Get the Stockscreener App
2.03
76.31%
-6.54
After Hours:
2.11
0.08
+3.94%
Applied Therapeutics Inc Stock (APLT) Latest News
Citigroup Issues Pessimistic Forecast for Applied Therapeutics (NASDAQ:APLT) Stock Price - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Price Target Lowered to $5.00 at Robert W. Baird - MarketBeat
Stock Traders Purchase High Volume of Applied Therapeutics Put Options (NASDAQ:APLT) - MarketBeat
RBC downgrades Applied Therapeutics as FDA rejects Govorestat, hacks price target - MSN
Applied Therapeutics CRL a ‘major setback,’ says William Blair - Yahoo Finance
Applied Therapeutics downgraded to Sector Perform from Outperform at RBC - Yahoo Finance
Biopharmaceutical Company's Stock Plunges 75% After FDA Rejects New Drug - International Business Times
Applied Therapeutics Stock Craters After FDA Rejects Rare Genetic Disorder Drug Candidate: Retail Mood Dented - MSN
Applied Therapeutics target lowered to $8, ‘catalyst watch’ removed at Citi - MSN
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76% - Yahoo Finance
Applied Therapeutics (APLT) Stock Plunges 75% as FDA Rules Against Genetic Drug - TipRanks
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow. - MSN
Baird cuts Applied Therapeutics stock target, but sees SORD deficiency approval as likely - Investing.com Nigeria
Baird cuts Applied Therapeutics stock target, but sees SORD deficiency approval as likely By Investing.com - Investing.com South Africa
RBC downgrades Applied Therapeutics سفخؤن to Sector Perform, sees potential in SORD deficiency - Investing.com India
Applied Therapeutics stock craters 75% on FDA setback - MSN
APLT Stock Plummets 76% After FDA Rejects Drug Approval - GuruFocus.com
Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug - Investopedia
Applied Therapeutics stock craters 75% on FDA setback (NASDAQ:APLT) - Seeking Alpha
Vestal Point Capital LP Has $9.73 Million Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Royal Bank of Canada Downgrades Applied Therapeutics (NASDAQ:APLT) to Sector Perform - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Applied Therapeutics, Inc. (APLT) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Why Is Applied Therapeutics Stock Trading Lower On Friday?Applied Therapeutics (NASDAQ:APLT) - Benzinga
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA - MSN
Applied Thera tanks, as FDA slaps CRL on govorestat NDA - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - AccessWire
Applied Therapeutics: FDA Denial Of Govorestat NDA As Problematic As It Was Unexpected - Seeking Alpha
Ally Bridge Group NY LLC Takes Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Wait for galactosemia therapy goes on after FDA shuns Applied Therapeutics’ govorestat - Yahoo Finance
Applied Tx craters as FDA rejects lead product candidate - pharmaphorum
FDA declines approval for Applied Therapeutics' Galactosemia drug By Investing.com - Investing.com South Africa
FDA declines approval for Applied Therapeutics' Galactosemia drug - Investing.com India
Applied Therapeutics plummets after FDA rejects govorestat - FirstWord Pharma
Applied Therapeutics Down 76% After Hours on FDA Complete Response Letter - Marketscreener.com
US FDA declines to approve Applied Therapeutics' genetic disease drug - MSN
Applied Therapeutics plunges 83% following Complete Response Letter - MSN
FDA declines to approve Applied Therapeutics' genetic disease drug govorestat - CNBC
Applied Therapeutics plunges 83% following Complete Response Letter (APLT:NASDAQ) - Seeking Alpha
FDA Issues CRL for Govorestat Application As Treatment for Classic Galactosemia - Neurology Live
Applied Therapeutics Receives FDA Complete Response Letter for Govorestat New Drug Application - MarketWatch
Applied Therapeutics’ NDA for govorestat receives negative response from FDA - TipRanks
Applied Therapeutics Receives Complete Response Letter from - GlobeNewswire
FDA Rejects Applied Therapeutics' Govorestat for Classic Galactosemia Treatment | APLT Stock News - StockTitan
Applied Therapeutics price target raised to $13 from $11 at Citi - TipRanks
APLT (Applied Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy - BioSpace
EmStop™ Announces Completion of CAPTURE-1 Early Feasibility Clinical Trial - Yahoo Finance
When (APLT) Moves Investors should Listen - Stock Traders Daily
Applied Therapeutics, Inc. (NASDAQ:APLT) Sees Large Drop in Short Interest - MarketBeat
Perceptive Advisors LLC Expands Stake in Applied Therapeutics Inc - GuruFocus.com
Alyeska Investment Group, L.P. Increases Stake in Applied Therap - GuruFocus.com
Janus Henderson Group PLC's Strategic Investment in Applied Ther - GuruFocus.com
Vestal Point Capital's Strategic Reduction in Applied Therapeuti - GuruFocus.com
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):